Novel chemotherapeutics and other therapies for treating high-grade glioma

Bibliography

• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170(5):1445–53
   PubMed Web of Science ®Google Scholar
• Altieri R, Agnoletti A, Quattrucci F, et al. Molecular biology of gliomas: present and future challenges. Transl Med UniSa 2014;10:29–37
   PubMedGoogle Scholar
• Bobek-Billewicz B, Stasik-Pres G, Hebda A, et al. Anaplastic transformation of low-grade gliomas (WHO II) on magnetic resonance imaging. Folia Neuropathol 2014;52(2):128–40
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97–109
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014;16(Suppl 4):iv1-63
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462–77
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98–110
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157–73
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987–96
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709–22
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):699–708
   PubMed Web of Science ®Google Scholar
• Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102(3):152–60
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997–1003
   PubMed Web of Science ®Google Scholar
• Buyse M, Michiels S, Sargent DJ, et al. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn 2011;11(2):171–82
   PubMed Web of Science ®Google Scholar
• Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120(6):707–18
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31(3):337–43
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17(5):510–22
   PubMed Web of Science ®Google Scholar
• Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013;126(3):443–51
   PubMed Web of Science ®Google Scholar
• Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56(21):5079–86
   PubMed Web of Science ®Google Scholar
• Nonoguchi N, Ohta T, Oh JE, et al. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013;126(6):931–7
   PubMed Web of Science ®Google Scholar
• Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110(15):6021–6
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061–8
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31(3):344–50
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707–15
   PubMed Web of Science ®Google Scholar
• Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27(35):5874–80
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345(8956):1008–12
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5(2):79–88
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190–8
   PubMed Web of Science ®Google Scholar
• Marko NF, Weil RJ, Schroeder JL, et al. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol 2014;32(8):774–82
   PubMed Web of Science ®Google Scholar
• Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115(1):3–8
   PubMed Web of Science ®Google Scholar
• Walker MD, Alexander EJr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49(3):333–43
   PubMed Web of Science ®Google Scholar
• Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 2010;17(7):1740–6
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Brem H. Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 2010;17(7):1729–31
   PubMed Web of Science ®Google Scholar
• Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010;33(4):441–9
   PubMed Web of Science ®Google Scholar
• Noel G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 2012;82(2):749–55
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Milanesi I, Silvani A, et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J Neurosurg 2013;118(4):821–9
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359(9311):1011–18
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733–40
   PubMed Web of Science ®Google Scholar
• Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174(4):1149–53
   PubMed Web of Science ®Google Scholar
• Tajik P, Zwinderman AH, Mol BW, Bossuyt PM. Trial designs for personalizing cancer care: a systematic review and classification. Clin Cancer Res 2013;19(17):4578–88
   PubMed Web of Science ®Google Scholar
• Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14(11):1131–8
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740–5
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci 2008;1142:108–32
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83(5):588–93
   PubMed Web of Science ®Google Scholar
• Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr Neurol Neurosci Rep 2011;11(3):305–12
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779–87
   PubMed Web of Science ®Google Scholar
• Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 2012;42(10):887–95
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;82(1):58–66
   PubMed Web of Science ®Google Scholar
• Tim Cloughesy EA. Survival analysis of patients with a PFS event who did not receive post-progression therapy in AVAglio (bevacizumab BEV. plus radiotherapy RT and temozolomide TMZ for newly diagnosed glioblastoma GBM). Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar
• Phillips H. Correlation of molecular subtypes with overall survival (OS) in AVAglio, a randomized, placebo-controlled study of bevacizumab plus radiotherapy and temozolomide for newly diagnosed glioblastoma. Paper presented at the Society of Neuro-Oncology; Miami, Florida: 2014
   Google Scholar
• Kreisl TN, Smith P, Sul J, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 2013;111(1):41–8
   PubMed Web of Science ®Google Scholar
• Hutterer M, Nowosielski M, Haybaeck J, et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol 2014;16(1):92–102
   PubMed Web of Science ®Google Scholar
• Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 2013;19(17):4816–23
   PubMed Web of Science ®Google Scholar
• Seystahl K, Weller M. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opin Investig Drugs 2012;21(5):605–17
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963–72
   PubMed Web of Science ®Google Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004;4(1):105–28
   PubMedGoogle Scholar
• Thomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging Therapies for Glioblastoma. JAMA Neurol 2014;71(11):1437–44
   PubMed Web of Science ®Google Scholar
• Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2012;2(5):458–71
   PubMed Web of Science ®Google Scholar
• Roskoski RJr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34–74
   PubMed Web of Science ®Google Scholar
• Wick W, Steinbach JP, Platten M, et al. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro Oncol 2013;15(10):1405–12
   PubMed Web of Science ®Google Scholar
• Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23(36):9359–68
   PubMed Web of Science ®Google Scholar
• Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005;16(10):1702–8
   PubMed Web of Science ®Google Scholar
• Gini B, Zanca C, Guo D, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res 2013;19(20):5722–32
   PubMed Web of Science ®Google Scholar
• Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22(18):2812–22
   PubMed Web of Science ®Google Scholar
• Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006;66(16):7864–9
   PubMed Web of Science ®Google Scholar
• Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20(6):810–17
   PubMed Web of Science ®Google Scholar
• Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 2006;65(4):1192–9
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 2013;85(5):1206–11
   PubMed Web of Science ®Google Scholar
• Reardon DA, Vredenburgh JJ, Desjardins A, et al. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol 2012;108(3):499–506
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462–77
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011;4:16
   PubMed Web of Science ®Google Scholar
• Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014;5(6):1515–25
   PubMed Web of Science ®Google Scholar
• Marian CO, Cho SK, McEllin BM, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010;16(1):154–63
   PubMed Web of Science ®Google Scholar
• Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013;39(5):444–56
   PubMed Web of Science ®Google Scholar
• Zhang PH, Zou L, Tu ZG. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 2006;131(1):143–9
   PubMed Web of Science ®Google Scholar
• Prins RM, Shu CJ, Radu CG, et al. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 2008;57(9):1279–89
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 1996;93(19):10399–404
   PubMed Web of Science ®Google Scholar
• Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977;25:1–54
   PubMed Web of Science ®Google Scholar
• Sankhla SK, Nadkarni JS, Bhagwati SN. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 1996;27(2):133–40
   PubMed Web of Science ®Google Scholar
• Wei J, Barr J, Kong LY, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010;16(2):461–73
   PubMed Web of Science ®Google Scholar
• Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006;8(3):261–79
   PubMed Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(31):4722–9
   PubMed Web of Science ®Google Scholar
• Robert Fenstermaker EA. Phase I study of safety, tolerability and immunologic effects of a survivin peptide mimic vaccine (SurVaxM) in patients with recurrent malignant glioma. Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar
• Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11(17):2389–401
   PubMed Web of Science ®Google Scholar
• Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 2008;28(8):1882–93
   PubMed Web of Science ®Google Scholar
• Koerber JT, Klimczak R, Jang JH, et al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009;17(12):2088–95
   PubMed Web of Science ®Google Scholar
• Annick Desjardins EA. Final results of a phase 1 trial of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against recurrent glioblastoma (GBM). Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar
• Schuessler A, Walker DG, Khanna R. Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front Oncol 2014;4:275
   PubMedGoogle Scholar
• Sonia Tejada EA. Preliminary results of the trial: "Phase I Trial of combination of DNX-2401 (formerly named Delta-24-RGD) oncolytic adenovirus with a short course of temozolomide for treatment of glioblastoma at first recurrence". Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar
• Patel MA, Kim JE, Ruzevick J, et al. The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) 2014;6(4):1953–85
   PubMedGoogle Scholar
• Ghazi A, Ashoori A, Hanley PJ, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother 2012;35(2):159–68
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009;8(10):2773–9
   PubMed Web of Science ®Google Scholar
• Thomas AA, Fisher JL, Ernstoff MS, Fadul CE. Vaccine-based immunotherapy for glioblastoma. CNS Oncol 2013;2(4):331–49
   Google Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Can Immu Immunot 2013;62(1):125–35
   PubMed Web of Science ®Google Scholar
• Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17(6):1603–15
   PubMed Web of Science ®Google Scholar
• Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 2014;74(13):3466–76
   PubMed Web of Science ®Google Scholar
• Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004;64(14):4980–6
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107(9):4275–80
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691–7
   PubMed Web of Science ®Google Scholar
• Westphal M, Heese O, Steinbach JP, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer 2015;51(4):522–32
   PubMed Web of Science ®Google Scholar
• Wygoda Z, Kula D, Bierzynska-Macyszyn G, et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma 2006;25(3):125–32
   PubMed Web of Science ®Google Scholar
• Liu TF, Hall PD, Cohen KA, et al. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 2005;11(1):329–34
   PubMed Web of Science ®Google Scholar
• Williams EL, Dunn SN, James S, et al. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res 2013;19(13):3545–55
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhang G, Zhang J, et al. A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol 2013;114(2):199–208
   PubMed Web of Science ®Google Scholar
• Cui L, Fu J, Pang JC, et al. Overexpression of IL-7 enhances cisplatin resistance in glioma. Cancer Biol Ther 2012;13(7):496–503
   PubMed Web of Science ®Google Scholar
• G Vlahovic EA. Pilot Study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed GBM. Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar
• Butowski N, Lamborn KR, Lee BL, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 2009;91(2):183–9
   PubMed Web of Science ®Google Scholar
• Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 2015. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21(17):3343–50
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18(2):226–32
   PubMed Web of Science ®Google Scholar
• Hunn MK, Bauer E, Wood CE, et al. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neurooncol 2014;121(2):319–29
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 2002;51(8):424–30
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329–60
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011;17(16):5473–80
   PubMed Web of Science ®Google Scholar
• Wen PY, Cloughesy TF, Ellingson BM, et al. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol 2014;16(Suppl 7):vii36–47
   PubMed Web of Science ®Google Scholar
• Everson RG, Jin RM, Wang X, et al. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2014;2:10
   PubMedGoogle Scholar
• Rubsam LZ, Boucher PD, Murphy PJ, et al. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res 1999;59(3):669–75
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13(1):84–8
   PubMed Web of Science ®Google Scholar
• Wei J. Glioma Associated cancer-initiating cells induce immune suppression. Clin Cancer Res 2010;16(2):461–73
   PubMed Web of Science ®Google Scholar
• Buonerba C, Di Lorenzo G, Marinelli A, et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol 2011;80(1):54–68
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008;10(3):320–9
   PubMed Web of Science ®Google Scholar
• Shahar T, Ram Z, Kanner AA. Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls. J Neurooncol 2012;107(2):373–8
   PubMed Web of Science ®Google Scholar
• Slegerova J, Hajek M, Rehor I, et al. Designing the nanobiointerface of fluorescent nanodiamonds: highly selective targeting of glioma cancer cells. Nanoscale 2014;7(2):415–20
   Web of Science ®Google Scholar
• Nance E, Zhang C, Shih TY, et al. Brain-penetrating nanoparticles improve Paclitaxel efficacy in malignant glioma following local administration. ACS Nano 2014;8(10):10655–64
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1100–8
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(16):2712–18
   PubMed Web of Science ®Google Scholar
• Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012;9(11):2961–73
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lam DH, Yang J, et al. Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors. Gene Ther 2012;19(2):189–200
   PubMed Web of Science ®Google Scholar
• Akhan E, Tuncel D, Akcali KC. Nanoparticle labeling of bone marrow-derived rat mesenchymal stem cells: their use in differentiation and tracking. Biomed Res Int 2015;2015:298430
   Web of Science ®Google Scholar
• da Fonseca CO, Schwartsmann G, Fischer J, et al. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 2008;70(3):259–66
   PubMed Web of Science ®Google Scholar
• Drappatz J, Brenner A, Wong ET, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 2013;19(6):1567–76
   PubMed Web of Science ®Google Scholar
• Huang T, Parab S, Burnett R, et al. Intravenous administration of a retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in an orthotopic immune-competent mouse glioma model. Hum Gene Ther 2014
   PubMed Web of Science ®Google Scholar
• Manish Aghi EA. Intratumoral delivery of the Retroviral Replicating Vector (RRV) Toca 511 in subjects with recurrent high grade glioma: Interim report of phase 1 study (NCT 01156584). Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar
• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48(14):2192–202
   PubMed Web of Science ®Google Scholar
• Roger Stupp EA. Interim analysis of the EF-14 trial: A prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM. Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar
• Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012;117(6):1032–8
   PubMed Web of Science ®Google Scholar
• Dincoglan F, Beyzadeoglu M, Sager O, et al. Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. Tumori 2015;101(2):179–84
   PubMed Web of Science ®Google Scholar
• Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 2013;15(2):242–50
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15(9):943–53
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117(23):5351–8
   PubMed Web of Science ®Google Scholar
• Alba A, Brandes EA. Final results from the randomized phase II trial AVAREG (ML25739) with bevacizumab (BEV) or fotemustine (FTM) in recurrent GBM. Paper presented at the Society of Neuro-oncology; Miami, FL: 2014
   Google Scholar